Given the growing interest in HMG CoA reductase inhibitors [58] and other potential adjunctive therapies targeting the endothelium in sepsis [55], better tools for monitoring the response of the endothelium in clinical trials are needed. The gene discussed is HMGCR; the disease is Sepsis.